The expression of IGF2BP3 is increased in many tumors, such as hepatocellular carcinoma, colorectal cancer, lung cancer, and breast cancer, and is associated with poor prognosis, indicating that IGF2BP3 may be a biomarker of malignant tumors. This evidence concerns the gene IGF2BP3 and colorectal cancer.